form patients that anaphylactic reactions have occurred in patients receiving sumatriptan. Suchreactions can be life threatening or fatal. In general, anaphylactic reactions to drugs are morelikely to occur in individuals with a history of sensitivity to multiple allergens [seeContraindications (4) and Warnings and Precautions (5.9)].
Concomitant Use with Other Triptans or Ergot MedicationsInform patients that use of TOSYMRA within 24 hours of another triptan or an ergot-typemedication (including dihydroergotamine or methylsergide) is contraindicated [seeContraindications (4), Drug Interactions (7.1, 7.3)].
Serotonin Syndrome
Caution patients about the risk of serotonin syndrome with the use of TOSYMRA or othertriptans, particularly during combined use with SSRIs, SNRIs, TCAs, and MAO inhibitors [seeWarnings and Precautions (5.7), Drug Interactions (7.4)].
Medication Overuse Headache
Inform patients that use of acute migraine drugs for 10 or more days per month may lead to anexacerbation of headache and encourage patients to record headache frequency and drug use(e.g., by keeping a headache diary) [see Warnings and Precautions (5.6)].
Pregnancy
Advise patients to notify their healthcare provider if they become pregnant during treatment orplan to become pregnant [see Use in Specific Populations (8.1)].
LactationAdvise patients to notify their healthcare provider if they are breastfeeding or plan to breastfeed[see Use in Specific Populations (8.2)].
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210884s000lbledt.pdf
|
